U.S. markets close in 37 minutes

China SXT Pharmaceuticals, Inc. (SXTC)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.4301-0.0299 (-2.05%)
As of 3:22PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
MACD

MACD

Previous Close1.4600
Open1.4200
Bid1.4300 x 800
Ask1.4400 x 800
Day's Range1.4100 - 1.4600
52 Week Range0.8880 - 5.1200
Volume160,061
Avg. Volume1,945,398
Market Cap22.187M
Beta (5Y Monthly)-0.22
PE Ratio (TTM)N/A
EPS (TTM)-0.6570
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • China SXT Pharmaceuticals, Inc. Announces 1 for 4 Reverse Share Split
    PR Newswire

    China SXT Pharmaceuticals, Inc. Announces 1 for 4 Reverse Share Split

    China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("TCMHS") announced today that a 1 for 4 reverse split of its ordinary shares was approved by the Company's board of directors on January 23, 2021 and is expected to become effective on February 19, 2021, China SXT's ordinary shares is expected to begin trading on a split-adjusted basis when the market opens on February 22, 2021.

  • Is China SXT Pharmaceuticals, Inc. (SXTC) A Good Stock To Buy?
    Insider Monkey

    Is China SXT Pharmaceuticals, Inc. (SXTC) A Good Stock To Buy?

    How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]

  • NASDAQ Granted China SXT Pharmaceuticals, Inc. 180-Day Extension to Regain Compliance with Bid Price Requirement
    PR Newswire

    NASDAQ Granted China SXT Pharmaceuticals, Inc. 180-Day Extension to Regain Compliance with Bid Price Requirement

    China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("TCMHS") announced today that on September 8, 2020, it received notification from NASDAQ granting the Company an additional 180-day period, or until March 8, 2021, to regain compliance with NASDAQ's minimum $1.00 bid price per share requirement of Nasdaq's Marketplace Rule 5550(a)(2) (the "Rule").